Cancer Immunotherapy Principles and Practice

Cancer Immunotherapy Principles and Practice, from the Society for Immunotherapy of Cancer (SITC), is the authoritative reference on cancer immunobiology and the immunotherapy treatments that harness the immune system to combat malignant disease.

Featuring five sections and over 50 chapters covering the Basic Principles of Tumor Immunology, Cancer Immunotherapy Targets and Classes, Immune Function in Cancer Patients, Disease-Specific Treatments and Outcomes, and Regulatory Aspects of Cancer Immunotherapy, this book covers all major topics that have shaped the development of immunotherapy and propelled it to its current place at the forefront of cancer treatment innovation.

This volume is a comprehensive resource for oncologists and fellows, immunologists, cancer researchers, and related practitioners seeking understanding of the basic science and clinical applications of cancer immunotherapy. As well as presenting the evidence for immune-based cancer treatment, it positions immunotherapy in the context of other available cancer treatments and provides data on response rates, risks, and toxicities across a variety of diseases. Filled with detailed tables, and instructive illustrations, as well as key points for quick reference, Cancer Immunotherapy Principles and Practice simplifies a challenging and dynamic subject.

Contents
Contributors
Preface
Acknowledgments
1. History of Cancer Immunotherapy

Section I - Basic principles of tumor immunology
. 2. Introduction to Basic Sciences—Cracking the Code of Cancer Immune Responsiveness and the Evolution of Cancer Biology
. 3. Human Tumor Antigens Recognized by T Lymphocytes
. 4. HLA Class I Antigen-Processing Machinery in Cancer
. 5. Systems Biology of T Cells
. 6. Activation of CD4+ T Lymphocytes
. 7. Regulation of Cell-Mediated Immunity: The Biology of Checkpoints and Regulatory T Cells
. 8. The Role of Breg Cells in Modulating the Antitumor Immune Response
. 9. The Innate Immune System: Natural Killer Cells
. 10. The Innate Immune System: Macrophages
. 11. Natural Killer Cell Effector Mechanisms Against Solid Tumors and Leukemias and Their Exploitation in Immunotherapy
. 12. Role of the Microbiota in Homeostasis, Carcinogenesis, and Therapy
. 13. Chemokines and Chemokine Receptors: Regulators of the Balance Between Antitumor and Protumor Immunity and Promising Targets in Cancer Immunotherapy
. 14. Role of the Tumor Microenvironment

. Section II - Cancer immunotherapy targets and classes
. 15. Introduction to Principles of Cancer Immunotherapy
. 16. Manipulating Innate Immune Pathways as Cancer Immunotherapy
. 17. Cancer Vaccines: Considerations of Antigen, Formulation, and Delivery
. 18. T Cell Modulatory Cytokines
. 19. Adoptive T Cell Transfer
. 20. Immunotherapy Based on Blocking T Cell Inhibitory Pathways
. 21. Agonistic Antibodies to Co-Stimulatory Molecules
. 22. Immune Effects of Conventional Cancer Therapeutics
. 23. Oncolytic Viruses
. 24. Principles of Combination Immunotherapies

Section III - Immune function in cancer patients
. 25. Introduction to Immune Function in Cancer Patients
. 26. Tumor-Infiltrating Immune Cells of Myeloid Origin
. 27. Intratumoral Gene Signatures and Host Genetic Variations Associated With Immune Responsiveness
. 28. Impact of Somatic Mutations on the Local and Systemic Antitumor Immune Response
. 29. Tumor Antigen Profiling
. 30. Assessment of Antitumor Immunity in Blood and Lymph Nodes
. 31. Regulatory T Cell Biology and Its Application in Cancer
. 32. Systemic Measures of Immune Function in Cancer Patients: Other Suppressive Cellular Mechanisms
. 33. Circulating Mediators of Tumor-Induced Immune Suppression
. 34. The Multifaceted Roles of B Cells and Plasma Cells in Antitumor Immunity
. 35. Systems Immunology Approaches to Cancer Immunotherapy
. 36. Tumor Microenvironment Metabolism as a Primordial Checkpoint in Antitumor T Cell Immunity
. 37. Age-Related Immune Function Changes as They Relate to Cancer Immunotherapy
. 38. Clinical Measures: Imaging, Pseudoprogression, and Metabolism

Section IV - Disease-specific treatments and outcomes
. 39. Introduction: General Approach to Cancer Immunotherapy—Lessons Learned From the Past Years
. 40. Immunotherapy in Melanoma
. 41. Other Cutaneous Tumors: Basal Cell Carcinoma, Cutaneous Squamous Cell Carcinoma, and Merkel Cell Carcinoma
. 42. Immunotherapy in Genitourinary Malignancies
. 43. Immunotherapy in Gastrointestinal Cancers
. 44. Immunotherapy of Hepatocellular Carcinoma
. 45. Immunotherapy for Gynecologic Malignancies
. 46. Breast Cancer Immunotherapy
. 47. Lung Cancer
. 48. Head and Neck Cancer
. 49. Immunotherapy of Hematologic Malignancies: Lymphomas, Leukemias, and Myeloma
. 50. Brain Tumors
. 51. Sarcomas
. 52. Pediatric Cancers: Neuroblastoma

Section V - Regulatory aspects of cancer immunotherapy
53. A Regulatory Perspective on Cell Therapy for Cancer: Chemistry, Manufacturing and Control, and Preclinical and Clinical Considerations
. 54. Gene Therapy-Based Immunotherapy Products for Human Clinical Trials: Chemistry, Manufacturing and Control, Preclinical and Clinical Considerations—An FDA Perspective
. 55. Regulatory Considerations for In Vitro Diagnostic Devices

Index